Equity · Healthcare
KNSA
NASDAQKiniksa Pharmaceuticals International (KNSA)
The line runs 83.18 USD on 20 October through 98.82 USD on 9 November, on a scale from 70 to 100. Days the market did not trade hold the previous close, flat.
- Market cap
- 8.3B USD
- P/E (TTM)
- 75.4
- Revenue, year to Dec 2025
- 677.6M USD
- EPS, diluted, year to Dec 2025
- 0.75 USD
- 52-week range
- 37 USD – 98.82 USD
- Avg volume
- 143.1K
- Mentions, 30 days
- 2
as of Nov 9, 2026
Have Kiniksa Pharmaceuticals International (KNSA) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Kiniksa Pharmaceuticals International insiders reported 11 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 29 May 2026, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 4 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 04 Nov 2026 | Patel Sanj KCHAIRMAN & CEO | Sell | 151,300 | 14.3M USD |
| 03 Nov 2026 | Patel Sanj KCHAIRMAN & CEO | Sell | 220,170 | 20.5M USD |
| 02 Nov 2026 | Patel Sanj KCHAIRMAN & CEO | Sell | 89,433 | 8.2M USD |
| 02 Nov 2026 | Paolini John F.CHIEF MEDICAL OFFICER | Sell | 18,413 | 1.7M USD |
| 02 Nov 2026 | Ragosa MarkCHIEF FINANCIAL OFFICER | Sell | 36,783 | 3.4M USD |
| 02 Nov 2026 | Moat RossCHIEF OPERATING OFFICER | Sell | 27,977 | 2.6M USD |
| 30 Oct 2026 | Megna Michael RCHIEF ACCOUNTING OFFICER | Sell | 36,260 | 3.4M USD |
| 30 Oct 2026 | Patel Sanj KCHAIRMAN & CEO | Sell | 92,891 | 8.6M USD |
| 30 Oct 2026 | Paolini John F.CHIEF MEDICAL OFFICER | Sell | 77,587 | 7.2M USD |
| 30 Oct 2026 | Moat RossCHIEF OPERATING OFFICER | Sell | 75,608 | 7.0M USD |
| 03 Sep 2026 | Megna Michael RCHIEF ACCOUNTING OFFICER | Sell | 4,600 | 369K USD |
| Sold | 11 open-market sales | 831,022 | $77.48M |
21 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 04 Nov 2026 | Patel Sanj KCHAIRMAN & CEO | Option exercise | 145,763 | 2.6M USD |
| 03 Nov 2026 | Patel Sanj KCHAIRMAN & CEO | Option exercise | 130,326 | 1.5M USD |
| 02 Nov 2026 | Patel Sanj KCHAIRMAN & CEO | Option exercise | 53,381 | 471K USD |
| 02 Nov 2026 | Paolini John F.CHIEF MEDICAL OFFICER | Option exercise | 18,413 | 414K USD |
| 02 Nov 2026 | Ragosa MarkCHIEF FINANCIAL OFFICER | Option exercise | 36,783 | 480K USD |
| 02 Nov 2026 | Moat RossCHIEF OPERATING OFFICER | Option exercise | 27,977 | 581K USD |
| 30 Oct 2026 | Megna Michael RCHIEF ACCOUNTING OFFICER | Option exercise | 19,895 | 253K USD |
| 30 Oct 2026 | Patel Sanj KCHAIRMAN & CEO | Option exercise | 47,530 | 420K USD |
| 30 Oct 2026 | Paolini John F.CHIEF MEDICAL OFFICER | Option exercise | 77,587 | 1.9M USD |
| 30 Oct 2026 | Moat RossCHIEF OPERATING OFFICER | Option exercise | 69,595 | 957K USD |
| 01 Sep 2026 | Megna Michael RCHIEF ACCOUNTING OFFICER | Option exercise | 11,496 | |
| 01 Sep 2026 | Megna Michael RCHIEF ACCOUNTING OFFICER | Tax withheld | 5,531 | 438K USD |
Showing the 12 most recent of 21 compensation filings in this window. The figures above count all of them.
Which funds hold Kiniksa Pharmaceuticals International (KNSA)?
1 of the 45 institutional funds we track reported a Kiniksa Pharmaceuticals International position for the quarter ended 30 Sep 2026 — a combined 24.2M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 323,808 | 24.2M USD | −18.7% |
What has been filed or recorded for Kiniksa Pharmaceuticals International (KNSA)?
The filings we hold for Kiniksa Pharmaceuticals International, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 1 shares | 79 USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.56 USD | Revenue $286M |
| 30 Sep 2026 | Financials | Total assets | 983.2M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 710.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.30 USD | Revenue $244M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.27 USD | Revenue $214M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.75 USD | Revenue $678M |
| 31 Dec 2025 | Financials | Revenue | 677.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 59.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.75 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.23 USD | Revenue $181M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.23 USD | Revenue $157M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.11 USD | Revenue $138M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.60 USD | Revenue $423M |
What is Reddit saying about Kiniksa Pharmaceuticals International (KNSA)?
Reddit mentioned KNSA 2 times in the 30 days to 10 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 10 November 2026.
30-day window, Method
How do Reddit mentions of Kiniksa Pharmaceuticals International (KNSA) compare with its price?
Share ↗
Which subreddits are talking about Kiniksa Pharmaceuticals International (KNSA)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 2 | +0.15 |
What do people ask about Kiniksa Pharmaceuticals International (KNSA)?
What did Kiniksa Pharmaceuticals International shares close at?98.82
Kiniksa Pharmaceuticals International closed at 98.82 USD on 9 Nov 2026, up 5.34% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Kiniksa Pharmaceuticals International’s market cap?8.3B
Kiniksa Pharmaceuticals International is worth 8.3B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Kiniksa Pharmaceuticals International’s P/E ratio?75.4
Kiniksa Pharmaceuticals International has a price-to-earnings ratio of 75.4, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Kiniksa Pharmaceuticals International’s revenue?677.6M
Kiniksa Pharmaceuticals International reported revenue of 677.6M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Kiniksa Pharmaceuticals International insiders bought or sold shares recently?11 sales
In the 90 days to 10 Nov 2026, Kiniksa Pharmaceuticals International insiders reported 11 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 29 May 2026, show no open-market purchase. A further 21 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Kiniksa Pharmaceuticals International?1 of 45
1 of the 45 funds we track reported a Kiniksa Pharmaceuticals International position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Kiniksa Pharmaceuticals International last report earnings?0.56
Kiniksa Pharmaceuticals International last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.56 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Kiniksa Pharmaceuticals International?0 mentions
Kiniksa Pharmaceuticals International was mentioned 0 times in the last 7 days across the finance subreddits we track, and 2 times over the trailing 30 days. Of the 2 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings